CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.44: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.51BCNY1.12B · vs all stocks (USD)
Revenue (TTM)
392.19MCNY58.32M · vs all stocks (USD)
Profit Margin
0.88%Beta
0.8940xvs all stocks
52-Week Change
10.38%vs all stocks
Market Capitalization
7.51BCNY1.12B · vs all stocks (USD)
Enterprise Value
7.92BCNY1.18B · vs all stocks (USD)
Forward P/E
-27.63xPrice to Sales (TTM)
19.79xPrice to Book (MRQ)
7.00xEnterprise to Revenue
20.19xGross Margin
94.01%Profit Margin
0.88%Operating Margin
76.03%Return on Assets (TTM)
0.36%Return on Equity (TTM)
0.31%Revenue (TTM)
392.19MCNY58.32M · vs all stocks (USD)
Revenue per Share (TTM)
1.05CNYUpdated Aug 21, 2026Quarterly Revenue Growth
948.90%Gross Profit (TTM)
308.24MCNY45.84M · vs all stocks (USD)
EBITDA (TTM)
29.59MCNY4.40M · vs all stocks (USD)
Net Income (TTM)
3.46MCNY514.87K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
685.46%Operating Cash Flow (TTM)
39.96MCNY5.94M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-128.04MCNY-19.04M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
123.39MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
82.40MCNYFY2025 · Dec 31, 2025Gross Profit
40.99MCNYFY2025 · Dec 31, 2025Operating Income
-241.02MCNY-35.84M · vs all stocks (USD)
Pre-tax Income
-268.05MCNYFY2025 · Dec 31, 2025Net Income
-268.05MCNYFY2025 · Dec 31, 2025EBIT
-258.94MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-190.19MCNYFY2025 · Dec 31, 2025Research & Development
141.54MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
90.84MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.28MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.12MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.7200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.7200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
372.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
372.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-268.05MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-305.82MCNYFY2025 · Dec 31, 2025Free Cash Flow
-335.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
170.34MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-268.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
9.22MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.87MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-29.83MCNYFY2025 · Dec 31, 2025Net Acquisitions
27.47MCNYFY2025 · Dec 31, 2025Sale of Investments
12.22MCNYFY2025 · Dec 31, 2025Other Investing Activity
162.82MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
172.68MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
361.85MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-362.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.19MCNYFY2025 · Dec 31, 2025Other Financing Charges
-15.46MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-24.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
374.58MSharesUpdated Aug 21, 2026Float Shares
216.86MSharesUpdated Aug 21, 2026% Held by Insiders
41.71%vs all stocks
% Held by Institutions
11.87%vs all stocks
Total Cash (MRQ)
729.72MCNY108.52M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.95CNYUpdated Aug 21, 2026Total Debt (MRQ)
471.59MCNY70.13M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4255xCurrent Ratio (MRQ)
3.54xBook Value per Share (MRQ)
2.96CNYUpdated Aug 21, 2026Total Assets
1.58BCNY234.71M · vs all stocks (USD)
Total Current Assets
1.00BCNYFY2025 · Dec 31, 2025Total Liabilities
701.44MCNYFY2025 · Dec 31, 2025Total Non-current Assets
573.49MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
291.10MCNYFY2025 · Dec 31, 2025Total Current Liabilities
410.34MCNYFY2025 · Dec 31, 2025Cash
170.13MCNYFY2025 · Dec 31, 2025Cash Equivalents
212.12KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
170.34MCNYFY2025 · Dec 31, 2025Other Short-term Investments
542.79MCNYFY2025 · Dec 31, 2025Accounts Receivable
58.49MCNYFY2025 · Dec 31, 2025Inventory
66.62MCNYFY2025 · Dec 31, 2025Accounts Payable
47.06MCNYFY2025 · Dec 31, 2025Short-term Debt
326.05MCNYFY2025 · Dec 31, 2025Other Current Liabilities
49.01KCNYFY2025 · Dec 31, 2025Long-term Debt
82.86MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
374.58MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.22BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
876.87MCNY130.40M · vs all stocks (USD)
52-Week Low
13.06CNYUpdated Aug 21, 202652-Week High
29.98CNYUpdated Aug 21, 202652-Week Change
10.38%vs all stocks
Beta
0.8940xvs all stocks
50-Day MA
21.29CNYUpdated Aug 21, 2026200-Day MA
20.97CNYUpdated Aug 21, 2026Avg 10-Day Volume
18.54MSharesUpdated Aug 21, 2026Avg 30-Day Volume
20.66MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.0100CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: 0.01
Financial Health
Altman Z-Score 4.44: safe zoneNotable
Altman Z-Score: 4.44
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule